Guardian Pharmacy Services (GRDN) drew investor attention after releasing second quarter 2026 results that showed higher sales and net income compared with a year earlier. The company also raised full year revenue guidance.

The latest earnings release and raised guidance have come after a strong period for Guardian Pharmacy Services, with a year to date share price return of 40.43% and a 1 year total shareholder return of 108.60%. This points to building momentum despite a 1 day share price decline of 5.38% to $41.47.

If these results have you looking beyond Guardian Pharmacy Services, it could be a good moment to see what else is gaining attention in healthcare. Take a look at our screener of 43 healthcare AI stocks.

Guardian Pharmacy Services looks like a solid operator with growing earnings and higher guidance, yet the share price pullback after a strong run raises a sharper question: Are you paying a fair price for that quality today?

Most Popular Narrative: 11.8% Undervalued

Guardian Pharmacy Services is trading at $41.47 against a widely followed fair value narrative of $47, which frames the current pullback as a valuation question rather than a simple change in sentiment.

Active but disciplined M&A, supported by a debt free balance sheet, strong cash conversion above 60% and a flexible shelf registration, positions Guardian to accelerate regional density and national scale, driving incremental revenue and operating leverage.

Want to see why this narrative supports a higher price tag for Guardian Pharmacy Services? The key is how future earnings, margins and valuation multiples are expected to interact. Curious which assumptions about revenue mix and profit conversion really carry the fair value?

Result: Fair Value of $47 (UNDERVALUED)

However, there are still pressure points that could flip the Guardian Pharmacy Services story, especially if reimbursement terms tighten or if recent acquisitions take longer to reach expected profitability.

Another View on Guardian Pharmacy Services Valuation

While the core narrative for Guardian Pharmacy Services points to an 11.8% discount to fair value at $47, the current P/E of about 39.9x tells a different story. It sits above the US Healthcare industry at 24.9x, its peer average of 39.3x, and a fair ratio of 26x. This signals meaningful downside risk if sentiment cools and the ratio moves toward that fair ratio level. How comfortable are you with paying this kind of premium for the earnings profile on offer?

Next Steps

The story so far on Guardian Pharmacy Services mixes optimism with clear valuation questions, which makes this a moment to look closely at the data yourself. If you want to see what has investors optimistic right now, check the 3 key rewards.

Looking for more investment ideas beyond Guardian Pharmacy Services?

If Guardian Pharmacy Services has sharpened your focus on valuations and quality, now is the time to expand your watchlist with other targeted ideas before the next move.

• Target potential mispricings by checking companies that screen as high quality and potentially overlooked using the screener containing 21 high quality undiscovered gems.
• Strengthen your downside protection by focusing on businesses that pass rigorous balance sheet and fundamentals checks with the solid balance sheet and fundamentals stocks screener (48 results).
• Build a more resilient core by shortlisting companies that show lower overall risk scores through the 83 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.